BioTools Innovator Webinar Series
The goal of the BioTools Innovator webinar series is to provide the life science tools ecosystem and our portfolio companies with guidance from experts in areas that are specific to the strategic needs outlined in our discussions and surveys.
Our virtual webinars consist of panelists addressing key questions supplied in advance by the BioTools Innovator Accelerator, as well as a general discussion on the topic within the context of the evolving life sciences tools ecosystem. Our webinars are live-streamed on our YouTube Channel and LinkedIn, and are available for viewing on this page.
Webinar Library
2025 Webinars Starting in June
2024 Webinar Schedule
*All webinars start at 9 AM PT unless otherwise noted. Webinars will be posted here, or may also be viewed on the BioTools Innovator LinkedIn page.
Aug
8
**By Invite Only Coming to Terms: Negotiating Term Sheets, SAFE Notes & Cap Tables
Perfecting Your Pitch Video
Co-founder and CEO of ImmersiveTouch, where we are reducing the standard 7-10 day 3D planning delivery down to just minutes. We are a pioneer in VR simulated surgical planning; the next dimension in personalized healthcare. ImmersiveTouch is highly differentiated with a large hospital base and patent portfolio. I’m responsible for running all facets of the business and have a proven executive management track record driving growth and innovation in healthcare. I am driven to improve healthcare economics and patient outcomes. I am an accomplished speaker, and a contributor to publications such as Forbes and Business Insider. Under my leadership ImmersiveTouch was awarded Best Video and Top 4 Finalist by MedTech Innovator, won the Center for Advancing Innovation Global Health Innovation Challenge; awarded Best Simulation Company in North America by Frost & Sullivan; listed in the 34 Virtual Reality Companies to Know by Built In; featured in Healthcare Tech Outlook ‘s Top 10 Medical Imaging Solutions Providers; named one of The 7 Virtual Reality Companies to Innovate Healthcare by Medical Design and Outsourcing; listed as one of The 9 Healthcare Companies Making Innovations in Virtual Reality by Touchstone Research; selected as one of the Top 10 Startups by HealthBox; and awarded Top Simulation Company by MedTech Outlook.
After earning a bachelor’s degree in Mechanical Engineering from Colorado State University, Mike went on to become a Nuclear Refueling Engineer for the Department of Defense’s submarine program.
Then, he and his wife relocated from Seattle, WA to San Diego, CA where he took an engineering position with Invetech, a Danaher company, and his wife, Dr. Leah Gordon, attended medical school.
While with Invetech, Mike worked as a senior mechanical engineer on a variety of projects supporting the development of diagnostic instruments, medical devices, cell and gene therapies, consumer products, and automation systems.
He currently operates his own consulting company, Michael Gordon, Inc, which specializes in the conceptualization, development and integration of novel technologies and biological workflows in the immuno-oncology/immunotherapy space.
I am the CEO and co-founder of Oxford Endovascular Ltd, a spinout from Oxford University.
The company is developing a revolutionary medical device to cure brain aneurysms; a life-threatening disease affecting 1 in 50 persons in a strongly growing market valued over $1 billion. In 2017 it won ‘Best Med-Tech Start-Up’ at the Oxford Bio Network awards, 1st place at the BioTrinity ‘Perfect Pitch’ competition, and an award at the ‘European Health Catapult’ finals.
I have nearly 30 years growing international businesses in large corporations & start-ups.
Experienced in strategic planning, execution, team building, gaining regulatory approvals & fundraising including winning a prestigious Horizon 2020 SME instrument grant amongst several others.
I mentor budding entrepreneurs, am a panelist at industry conferences and sit on the ‘Medfit’ steering committee in Paris, France.
Leadership pods and how to make the most of your mentorship
Curious by nature, I am constantly looking for challenges. I am the CEO and co-founder of Limula. We are located in Lausanne, Switzerland, and we develop a platform for closed and automated manufacturing of cell therapies.
Before launching Limula, I was a personal advisor to EPFL President Martin Vetterli. I graduated from the University of Oxford with a DPhil (PhD) in Chemical Biology – I am a skilled scientist, with a broad practical and theoretical background in chemistry, biotechnology and immunology.
Over the past 5 years, I have raised over CHF 10 Mio in non-dilutive funding for a series of innovative projects. I am particularly interested in cutting edge (bio)technologies, their societal impact, and how open innovation/science practices can catalyse the translation of R&D results.
A strong team player and avid networker, I combine my interpersonal, analytical and communication skills to build successful projects. I rapidly adapt and easily function in complex, diverse and dynamic environments. I am organised, detail-oriented, independent and entrepreneurial, with a strong ability to multi-task. My impeccable work ethic, commitment and loyalty to my colleagues make me a trusted partner.Curious by nature, I am constantly looking for challenges. I am the CEO and co-founder of Limula. We are located in Lausanne, Switzerland, and we develop a platform for closed and automated manufacturing of cell therapies. Before launching Limula, I was a personal advisor to EPFL President Martin Vetterli. I graduated from the University of Oxford with a DPhil (PhD) in Chemical Biology – I am a skilled scientist, with a broad practical and theoretical background in chemistry, biotechnology and immunology. Over the past 5 years, I have raised over CHF 10 Mio in non-dilutive funding for a series of innovative projects. I am particularly interested in cutting edge (bio)technologies, their societal impact, and how open innovation/science practices can catalyse the translation of R&D results. A strong team player and avid networker, I combine my interpersonal, analytical and communication skills to build successful projects. I rapidly adapt and easily function in complex, diverse and dynamic environments. I am organised, detail-oriented, independent and entrepreneurial, with a strong ability to multi-task. My impeccable work ethic, commitment and loyalty to my colleagues make me a trusted partner.
Mason developed the DynaCHIP technology for his PhD dissertation at the Georgia Institute of Technology under Andrei G. Fedorov. During his postdoc, Mason served as the entrepreneurial and technical lead for the project, securing Biolocity and Georgia Research Alliance funding to support the development of the technology. Mason formally cofounded Andson Biotech with Andrei just before it was backed by the well-known accelerator, Ycombinator, for their Winter 2022 batch. Under Mason’s leadership, Andson was selected into Merck Pharmaceutical’s inaugural accelerator program, the Merck Digital Sciences Studio (2022-2023), as well as the prestigious BioTools Innovator program (2023), where Andson was selected as a top 4 finalist. Mason has served as a consultant on projects ranging from artificial intelligence cancer diagnosis to resonance-based diagnostics sensors. Before starting his PhD, Mason worked in hands on roles that have benefitted him tremendously as an engineer including a position at a sheet metal/frame shop and as a design engineer for a pharmaceutical packaging company.